Xin Lang Cai Jing·2025-09-02 03:22Core Viewpoint - Junshi Bioscience's stock price has shown significant growth this year, with a 68.90% increase, despite a recent decline in trading activity and net outflow of funds [2][1]. Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and is involved in various concepts including monkeypox, mid-cap, margin trading, and biomedicine [2]. Financial Performance - For the first half of 2025, Junshi Bioscience reported revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 31,200, up by 5.88%, with an average of 24,543 circulating shares per person, a decrease of 5.56% [2]. - The top ten circulating shareholders include notable ETFs, with changes in their holdings indicating varying levels of investment interest [3].